

Please indicate your knowledge level on prevention and treatment of coronavirus-related human diseases

<b>main_question</b>	<b>n</b>	<b>%</b>
I have good knowledge	735	57.6%
I have some knowledge	495	38.8%
I have no knowledge	45	3.5%
Total	1275	

Is it likely that a vaccine for COVID-19 will be available in the next 18 months?

<b>knowledge</b>	<b>total_knowledge</b>	<b>answer_vac1</b>	<b>n</b>	<b>%</b>
Good knowledge	729	Likely	457	37.5%
Good knowledge	729	Unlikely	167	13.7%
Good knowledge	729	Unknown	105	8.6%
Some knowledge	490	Likely	309	25.3%
Some knowledge	490	Unlikely	122	10.0%
Some knowledge	490	Unknown	59	4.8%
Total	1219			

In the next 18 months, of all vaccine candidates currently in phase 1 or 2 clinical trials, which of these do you consider most likely to succeed in preventing COVID-19? + Which of all vaccine candidates currently in phase 1 or 2 clinical trials do you consider most likely to succeed in preventing COVID-19?

knowledge	Total	answer_vac1	answer_vac2	n	%
Good knowledge	435	Likely	Pathogen-specific aAPC from Shenzhen Geno-Immune Medical Institute	16	1.6%
Good knowledge	435	Likely	Ad5-nCoV from CanSino Biologicals	26	2.6%
Good knowledge	435	Likely	INO-4800 from Inovio Pharmaceuticals	8	0.8%
Good knowledge	435	Likely	LV-SMENP-DC from Shenzhen Geno-Immune Medical Institute	5	0.5%
Good knowledge	435	Likely	mRNA-1273 from Moderna	39	3.9%
Good knowledge	435	Likely	ChAdOx1 from University of Oxford	100	9.9%
Good knowledge	435	Likely	Other	31	3.1%
Good knowledge	435	Likely	Unknown	105	10.4%
Good knowledge	435	Likely	I prefer not to answer	105	10.4%
Good knowledge	160	Unlikely	Pathogen-specific aAPC from Shenzhen Geno-Immune Medical Institute	1	0.1%
Good knowledge	160	Unlikely	Ad5-nCoV from CanSino Biologicals	3	0.3%
Good knowledge	160	Unlikely	INO-4800 from Inovio Pharmaceuticals	1	0.1%
Good knowledge	160	Unlikely	LV-SMENP-DC from Shenzhen Geno-Immune Medical Institute	2	0.2%
Good knowledge	160	Unlikely	mRNA-1273 from Moderna	14	1.4%
Good knowledge	160	Unlikely	ChAdOx1 from University of Oxford	35	3.5%
Good knowledge	160	Unlikely	Other	6	0.6%
Good knowledge	160	Unlikely	Unknown	55	5.5%
Good knowledge	160	Unlikely	I prefer not to answer	43	4.3%
Some knowledge	296	Likely	Pathogen-specific aAPC from Shenzhen Geno-Immune Medical Institute	10	1.0%
Some knowledge	296	Likely	Ad5-nCoV from CanSino Biologicals	7	0.7%
Some knowledge	296	Likely	INO-4800 from Inovio Pharmaceuticals	4	0.4%
Some knowledge	296	Likely	LV-SMENP-DC from Shenzhen Geno-Immune Medical Institute	6	0.6%
Some knowledge	296	Likely	mRNA-1273 from Moderna	16	1.6%
Some knowledge	296	Likely	ChAdOx1 from University of Oxford	45	4.5%
Some knowledge	296	Likely	Other	19	1.9%
Some knowledge	296	Likely	Unknown	114	11.3%
Some knowledge	296	Likely	I prefer not to answer	75	7.4%
Some knowledge	117	Unlikely	Pathogen-specific aAPC from Shenzhen Geno-Immune Medical Institute	0	0.0%
Some knowledge	117	Unlikely	Ad5-nCoV from CanSino Biologicals	3	0.3%
Some knowledge	117	Unlikely	INO-4800 from Inovio Pharmaceuticals	0	0.0%
Some knowledge	117	Unlikely	LV-SMENP-DC from Shenzhen Geno-Immune Medical Institute	0	0.0%
Some knowledge	117	Unlikely	mRNA-1273 from Moderna	5	0.5%
Some knowledge	117	Unlikely	ChAdOx1 from University of Oxford	12	1.2%
Some knowledge	117	Unlikely	Other	7	0.7%
Some knowledge	117	Unlikely	Unknown	57	5.7%
Some knowledge	117	Unlikely	I prefer not to answer	33	3.3%
Total	1008				

In the next six months, which one of these broad approaches do you consider most likely to succeed as COVID-19 treatment?

<b>knowledge</b>	<b>total_knowledge</b>	<b>answer_drug1</b>	<b>n</b>	<b>%</b>
Good knowledge	694	Antivirals and antiretrovirals	311	26.8%
Good knowledge	694	Antimalarials	17	1.5%
Good knowledge	694	Antibiotics	5	0.4%
Good knowledge	694	Angiotensin-converting-enzyme (ACE) inhibitors	23	2.0%
Good knowledge	694	Anti-inflammatories	40	3.5%
Good knowledge	694	Non-drug technologies (e.g. plasma, stem-cells)	83	7.2%
Good knowledge	694	Monoclonal antibodies	114	9.8%
Good knowledge	694	Kinase inhibitors	2	0.2%
Good knowledge	694	Other	24	2.1%
Good knowledge	694	Unknown	47	4.1%
Good knowledge	694	I prefer not to answer	28	2.4%
Some knowledge	465	Antivirals and antiretrovirals	168	14.5%
Some knowledge	465	Antimalarials	15	1.3%
Some knowledge	465	Antibiotics	3	0.3%
Some knowledge	465	Angiotensin-converting-enzyme (ACE) inhibitors	26	2.2%
Some knowledge	465	Anti-inflammatories	46	4.0%
Some knowledge	465	Non-drug technologies (e.g. plasma, stem-cells)	35	3.0%
Some knowledge	465	Monoclonal antibodies	86	7.4%
Some knowledge	465	Kinase inhibitors	6	0.5%
Some knowledge	465	Other	17	1.5%
Some knowledge	465	Unknown	48	4.1%
Some knowledge	465	I prefer not to answer	15	1.3%
Total	1159			

In the next six months, of all \*drugs\* with at least two registred clinical trials, which one of these do you consider most likely to succeed as COVID-19 treatment?

<b>knowledge</b>	<b>Total</b>	<b>answer_vac1</b>	<b>answer_vac2</b>	<b>n</b>	<b>%</b>
Good knowledge	305	Antivirals and antiretrovirals	Favipiravir	13	1.3%
Good knowledge	305	Antivirals and antiretrovirals	I prefer not to answer	21	2.2%
Good knowledge	305	Antivirals and antiretrovirals	Interferons	18	1.9%
Good knowledge	305	Antivirals and antiretrovirals	Lopinavir-ritonavir	17	1.8%
Good knowledge	305	Antivirals and antiretrovirals	Other	26	2.7%
Good knowledge	305	Antivirals and antiretrovirals	Remdesivir	162	16.8%
Good knowledge	305	Antivirals and antiretrovirals	Umifenovir	3	0.3%
Good knowledge	305	Antivirals and antiretrovirals	Unknown	45	4.7%
Some knowledge	166	Antivirals and antiretrovirals	Favipiravir	12	1.2%
Some knowledge	166	Antivirals and antiretrovirals	I prefer not to answer	13	1.3%
Some knowledge	166	Antivirals and antiretrovirals	Interferons	10	1.0%
Some knowledge	166	Antivirals and antiretrovirals	Lopinavir-ritonavir	7	0.7%
Some knowledge	166	Antivirals and antiretrovirals	Other	9	0.9%
Some knowledge	166	Antivirals and antiretrovirals	Remdesivir	64	6.6%
Some knowledge	166	Antivirals and antiretrovirals	Umifenovir	0	0.0%
Some knowledge	166	Antivirals and antiretrovirals	Unknown	51	5.3%
Good knowledge	17	Antimalarials	Hydroxychloroquine	14	1.4%
Good knowledge	17	Antimalarials	I prefer not to answer	1	0.1%
Good knowledge	17	Antimalarials	Mefloquine	1	0.1%
Good knowledge	17	Antimalarials	Unknown	1	0.1%
Some knowledge	15	Antimalarials	Chloroquine	1	0.1%
Some knowledge	15	Antimalarials	Hydroxychloroquine	12	1.2%
Some knowledge	15	Antimalarials	I prefer not to answer	1	0.1%
Some knowledge	15	Antimalarials	Unknown	1	0.1%
Good knowledge	5	Antibiotics	Azithromycin	3	0.3%
Good knowledge	5	Antibiotics	Other	1	0.1%
Good knowledge	5	Antibiotics	Unknown	1	0.1%
Some knowledge	3	Antibiotics	Azithromycin	1	0.1%
Some knowledge	3	Antibiotics	Other	0	0.0%
Some knowledge	3	Antibiotics	Unknown	2	0.2%
Good knowledge	23	Angiotensin-converting-enzyme (ACE) inhibitors	Captopril	1	0.1%
Good knowledge	23	Angiotensin-converting-enzyme (ACE) inhibitors	I prefer not to answer	4	0.4%
Good knowledge	23	Angiotensin-converting-enzyme (ACE) inhibitors	Other	1	0.1%
Good knowledge	23	Angiotensin-converting-enzyme (ACE) inhibitors	Recombinant human angiotensin converting enzyme 2	11	1.1%
Good knowledge	23	Angiotensin-converting-enzyme (ACE) inhibitors	Telmisartan	0	0.0%

Good knowledge	23	Angiotensin-converting-enzyme (ACE) inhibitors	Unknown	6	0.6%
Some knowledge	26	Angiotensin-converting-enzyme (ACE) inhibitors	I prefer not to answer	2	0.2%
Some knowledge	26	Angiotensin-converting-enzyme (ACE) inhibitors	Losartan	1	0.1%
Some knowledge	26	Angiotensin-converting-enzyme (ACE) inhibitors	Other	2	0.2%
Some knowledge	26	Angiotensin-converting-enzyme (ACE) inhibitors	Recombinant human angiotensin converting enzyme 2	9	0.9%
Some knowledge	26	Angiotensin-converting-enzyme (ACE) inhibitors	Telmisartan	3	0.3%
Some knowledge	26	Angiotensin-converting-enzyme (ACE) inhibitors	Unknown	9	0.9%
Good knowledge	39	Anti-inflammatories	Ciclesonide	0	0.0%
Good knowledge	39	Anti-inflammatories	Dexamethasone	3	0.3%
Good knowledge	39	Anti-inflammatories	I prefer not to answer	7	0.7%
Good knowledge	39	Anti-inflammatories	Methylprednisolone	4	0.4%
Good knowledge	39	Anti-inflammatories	Other	14	1.4%
Good knowledge	39	Anti-inflammatories	Prednisone	2	0.2%
Good knowledge	39	Anti-inflammatories	Unknown	9	0.9%
Some knowledge	45	Anti-inflammatories	Ciclesonide	2	0.2%
Some knowledge	45	Anti-inflammatories	Dexamethasone	4	0.4%
Some knowledge	45	Anti-inflammatories	I prefer not to answer	6	0.6%
Some knowledge	45	Anti-inflammatories	Methylprednisolone	4	0.4%
Some knowledge	45	Anti-inflammatories	Other	6	0.6%
Some knowledge	45	Anti-inflammatories	Prednisone	1	0.1%
Some knowledge	45	Anti-inflammatories	Unknown	22	2.3%
Good knowledge	112	Monoclonal antibodies	Bevacizumab	0	0.0%
Good knowledge	112	Monoclonal antibodies	I prefer not to answer	24	2.5%
Good knowledge	112	Monoclonal antibodies	Leronlimab	2	0.2%
Good knowledge	112	Monoclonal antibodies	Nivolumab	2	0.2%
Good knowledge	112	Monoclonal antibodies	Other	20	2.1%
Good knowledge	112	Monoclonal antibodies	Sarilumab	0	0.0%
Good knowledge	112	Monoclonal antibodies	Tocilizumab	22	2.3%
Good knowledge	112	Monoclonal antibodies	Unknown	42	4.3%
Some knowledge	84	Monoclonal antibodies	Bevacizumab	2	0.2%
Some knowledge	84	Monoclonal antibodies	I prefer not to answer	15	1.6%
Some knowledge	84	Monoclonal antibodies	Leronlimab	2	0.2%
Some knowledge	84	Monoclonal antibodies	Nivolumab	1	0.1%
Some knowledge	84	Monoclonal antibodies	Other	11	1.1%
Some knowledge	84	Monoclonal antibodies	Sarilumab	3	0.3%
Some knowledge	84	Monoclonal antibodies	Tocilizumab	13	1.3%

Some knowledge	84	Monoclonal antibodies	Unknown	37	3.8%
Good knowledge	2	Kinase inhibitors	Acalabrutinib	0	0.0%
Good knowledge	2	Kinase inhibitors	Imatinib	0	0.0%
Good knowledge	2	Kinase inhibitors	Other	0	0.0%
Good knowledge	2	Kinase inhibitors	Unknown	2	0.2%
Some knowledge	6	Kinase inhibitors	Acalabrutinib	1	0.1%
Some knowledge	6	Kinase inhibitors	Imatinib	2	0.2%
Some knowledge	6	Kinase inhibitors	Other	1	0.1%
Some knowledge	6	Kinase inhibitors	Unknown	2	0.2%
Good knowledge	83	Non-drug technologies (e.g. plasma, stem-cells)	Immunoglobulin from cured patients	47	4.9%
Good knowledge	83	Non-drug technologies (e.g. plasma, stem-cells)	Natural-killer cells	2	0.2%
Good knowledge	83	Non-drug technologies (e.g. plasma, stem-cells)	Other	0	0.0%
Good knowledge	83	Non-drug technologies (e.g. plasma, stem-cells)	Plasma	27	2.8%
Good knowledge	83	Non-drug technologies (e.g. plasma, stem-cells)	Stem-cells	5	0.5%
Good knowledge	83	Non-drug technologies (e.g. plasma, stem-cells)	Unknown	2	0.2%
Some knowledge	35	Non-drug technologies (e.g. plasma, stem-cells)	Immunoglobulin from cured patients	17	1.8%
Some knowledge	35	Non-drug technologies (e.g. plasma, stem-cells)	Natural-killer cells	1	0.1%
Some knowledge	35	Non-drug technologies (e.g. plasma, stem-cells)	Other	1	0.1%
Some knowledge	35	Non-drug technologies (e.g. plasma, stem-cells)	Plasma	11	1.1%
Some knowledge	35	Non-drug technologies (e.g. plasma, stem-cells)	Stem-cells	1	0.1%
Some knowledge	35	Non-drug technologies (e.g. plasma, stem-cells)	Unknown	4	0.4%
Total	966				

What is the highest degree of education you have completed?

<b>knowledge</b>	<b>total_knowledge</b>	<b>answer_vac1</b>	<b>n</b>	<b>%</b>
Good knowledge	626	Associate's degree	11	1.0%
Good knowledge	626	Bachelor's degree	9	0.9%
Good knowledge	626	Doctoral degree	555	52.9%
Good knowledge	626	Master's degree	51	4.9%
Some knowledge	424	Associate's degree	5	0.5%
Some knowledge	424	Bachelor's degree	14	1.3%
Some knowledge	424	Doctoral degree	358	34.1%
Some knowledge	424	Master's degree	47	4.5%
Total	1050			



Which occupation type best applies to you?

<b>knowledge</b>	<b>total_knowledge</b>	<b>answer_vac1</b>	<b>n</b>	<b>%</b>
Good knowledge	633	Manager, Executive	13	1.2%
Good knowledge	633	Masters, PhD Student	26	2.5%
Good knowledge	633	Other	27	2.5%
Good knowledge	633	Physician, Clinician	68	6.4%
Good knowledge	633	Policy maker	3	0.3%
Good knowledge	633	Professor, Researcher	450	42.5%
Good knowledge	633	Public Health, Healthcare Professional	46	4.3%
Some knowledge	426	Manager, Executive	6	0.6%
Some knowledge	426	Masters, PhD Student	29	2.7%
Some knowledge	426	Other	24	2.3%
Some knowledge	426	Physician, Clinician	20	1.9%
Some knowledge	426	Policy maker	1	0.1%
Some knowledge	426	Professor, Researcher	314	29.7%
Some knowledge	426	Public Health, Healthcare Professional	32	3.0%

1059

What type of institution do you work in?

<b>knowledge</b>	<b>total_knowledge</b>	<b>answer_vac1</b>	<b>n</b>	<b>%</b>
Good knowledge	628	Government	67	6.4%
Good knowledge	628	Hospital or similar organizations	69	6.5%
Good knowledge	628	Industry	26	2.5%
Good knowledge	628	University, Research Organization	466	44.2%
Some knowledge	426	Government	59	5.6%
Some knowledge	426	Hospital or similar organizations	35	3.3%
Some knowledge	426	Industry	18	1.7%
Some knowledge	426	University, Research Organization	314	29.8%
Total	1054			

How many years of experience you have in your field?

<b>knowledge</b>	<b>total_knowledge</b>	<b>answer_vac1</b>	<b>n</b>	<b>%</b>
Good knowledge	634	Between 10 and 20 years	195	18.4%
Good knowledge	634	Between 5 and 10 years	83	7.8%
Good knowledge	634	Less than 5 years	33	3.1%
Good knowledge	634	More than 20 years	323	30.4%
Some knowledge	427	Between 10 and 20 years	139	13.1%
Some knowledge	427	Between 5 and 10 years	78	7.4%
Some knowledge	427	Less than 5 years	40	3.8%
Some knowledge	427	More than 20 years	170	16.0%
Total	1061			

In which region do you live?

<b>knowledge</b>	<b>total knowledge</b>	<b>answer_vac1</b>	<b>n</b>	<b>%</b>
Good knowledge	633	Africa	43	4.1%
Good knowledge	633	Asia (including Middle East)	127	12.0%
Good knowledge	633	Australasia or Pacific Islands	17	1.6%
Good knowledge	633	Europe	163	15.4%
Good knowledge	633	North America (including Central America and the Caribbean)	170	16.0%
Good knowledge	633	South America	113	10.7%
Some knowledge	427	Africa	33	3.1%
Some knowledge	427	Asia (including Middle East)	97	9.2%
Some knowledge	427	Australasia or Pacific Islands	17	1.6%
Some knowledge	427	Europe	128	12.1%
Some knowledge	427	North America (including Central America and the Caribbean)	82	7.7%
Some knowledge	427	South America	70	6.6%
Total	1060			